Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab Combination in Advanced NSCLC
NCT00870870Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2009
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Mar 2009; status: completed.
02
Drugs
cixutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00870870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00870870.